

Published in final edited form as:

Nat Immunol. 2013 June; 14(6): 527-529. doi:10.1038/ni.2612.

## PLA2G3 promotes mast cell maturation and function

Philipp Starkl<sup>1,3</sup>, Thomas Marichal<sup>1,3</sup>, and Stephen J. Galli<sup>1,2,\*</sup>

<sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, California 94305-5324, USA

<sup>2</sup>Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California 94305-5324, USA

## Summary

Mast cell-derived group III phospholipase A2 (PLA2G3) and fibroblast prostaglandin synthase contribute to a PGD<sub>2</sub> and mast-cell-DP-1-dependent mast cell-fibroblast paracrine axis that can enhance mast cell maturation and mediator secretion.

> Mast cells are derived from hematopoietic precursors that complete their differentiation and maturation in the microenvironments of virtually all vascularized tissues<sup>1</sup>. Mast cells are best known as key effector cells in acute IgE-associated disorders, including anaphylaxis, an immediate and potentially catastrophic systemic response initiated when antigen crosslinks antigen-specific IgE antibodies bound to high-affinity FceRI receptors on the mast cell plasma membrane, thereby initiating mast cell activation<sup>2</sup>. Mast cells activated by IgE and antigen degranulate (i.e., rapidly release pre-formed, granule-stored bioactive compounds) and also secrete newly formed lipid mediators and a large variety of growth factors, cytokines and chemokines that participate in hypersensitivity reactions<sup>2</sup>.

> The types and/or amounts of mediators released by mast cells activated by particular signals (including IgE and specific antigen) can be influenced, or "tuned", by many factors<sup>3</sup>. Among them, the stage of mast cell maturation influences the types and quantities of mediators stored in mast cell cytoplasmic granules and other features of mast cell phenotype<sup>1,3</sup>. The local development and maturation of mast cells is thought to be regulated by signals provided by structural cells in local tissue microenvironments, such as the c-Kit ligand, SCF (stem cell factor)<sup>1,3</sup>. Indeed, mice with loss-of-function mutations in both copies of the genes encoding SCF or c-Kit (CD117) are profoundly mast cell-deficient, reflecting the importance of SCF and c-Kit in mast cell development and survival in vivo<sup>1,3</sup>. However, our understanding of the regulation of mast cell maturation is by no means complete. In the current issue of Nature Immunology, Taketomi et al. describe a novel lipidbased mast cell-fibroblast interaction pathway which contributes to normal maturation of mouse peritoneal, skin and small intestinal mast cells in vivo<sup>4</sup>. The authors report that a mast cell-secreted group III phospholipase A2 (PLA2G3) plays a central role in this maturation mechanism and consequently also increases the intensity of biological responses involving IgE-dependent mast cell activation<sup>4</sup>.

> Phospholipase A2s (PLA2s) were originally discovered as toxic components of snake venoms<sup>5</sup>. PLA<sub>2</sub>s have a high proportion of cysteine (more than 10% of all amino acids) and a high prevalence of disulfide bridges<sup>5</sup>. The PLA<sub>2</sub> superfamily is divided into subgroups

<sup>\*</sup>Corresponding author: Stephen J. Galli Department of Pathology, L-235, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5324, Tel: 650-723-7975, Fax: 650-725-6902, sgalli@stanford.edu. 3these authors contributed equally to this work

based on the number and location of disulfide bridges, with groups I, II and III being originally characterized by PLA<sub>2</sub>s isolated from cobra, rattlesnake and honeybee venoms, respectively (with honeybee PLA<sub>2</sub> being significantly different structurally from the two snake venom PLA<sub>2</sub>s)<sup>5</sup>. However, all PLA<sub>2</sub>s share the ability to cleave fatty acids at the sn-2 position of glycerophospholipids, thereby generating free fatty acids and lysophospholipids<sup>5</sup>. Major biological functions of secreted mammalian PLA<sub>2</sub>s (sPLA<sub>2</sub>s; including groups I, II and III enzymes) include, but are not limited to, the metabolism of dietary phospholipids and contributions to skin homeostasis and host defense against bacteria and viruses<sup>5,6</sup> (Fig. 1, **step 3**).

PLA<sub>2</sub>s isolated from certain snake venoms and, with less potency, from honeybee venom, are known to induce antigen-independent degranulation of mouse and human mast cells *in vitro*<sup>7</sup> (Fig. 1, **step 1**). Earlier work by Murakami *et al.* showed that rat or mouse mast cells also can be activated *in vitro* by purified rat group II PLA<sub>2</sub><sup>8</sup>. Such group II sPLA<sub>2</sub>s can be released by mast cells, platelets and other cell types<sup>8,9</sup>, raising the possibility of autocrine or paracrine mechanisms of sPLA<sub>2</sub>-dependent mast cell activation *in vivo* (Fig. 1, **steps 2 and 4**). The ability of sPLA<sub>2</sub>s to induce mast cell degranulation was reported to depend on their enzymatic activity<sup>7–9</sup>. However, the systemic toxicity of venom sPLA<sub>2</sub>s (e.g., neurotoxicity) is thought also to be related to complex formation with other toxic venom compounds and their interaction with target molecules expressed in different tissues and organs<sup>10</sup>.

Mammalian PLA2G3 is a multidomain protein with a central 150 amino acid (AA) PLA2 domain flanked by N-terminal (130 AA) and C-terminal (219 AA) extensions with unknown functions <sup>11</sup>. Compared to venom PLA2s, the PLA2 domain of PLA2G3 has moderate overall amino acid sequence homology to PLA2s from the venoms of the Gila monster lizard and the honeybee (46% and 31%, respectively) and relatively high homology in the conserved calcium binding loop (73% and 64%, respectively) and active site regions (54%), and has therefore been assigned to group III <sup>11</sup>. It was shown recently that PLA2G3 potentially contributes to sperm maturation and to the development of atherosclerosis in mice<sup>5,6</sup>.

In the current study, Taketomi et al. first show that high amounts of purified honeybee venom PLA2 and recombinant human PLA2G3 can induce tissue oedema in mouse ear pinnae by inducing mast cell degranulation, and identify PLA2G3 as a cytoplasmic (and perhaps granule-associated) sPLA<sub>2</sub> in mouse mast cells<sup>4</sup> (Fig. 1). Using mice systemically deficient for Pla2g3 or other sPLA2s, mice overexpressing human Pla2g3 and mast celldeficient mice engrafted with bone marrow-derived cultured mast cells from different transgenic mouse strains, the authors show that PLA2G3 (but none of the other tested sPLA<sub>2</sub>s) can contribute to the intensity of IgE- and mast cell-dependent passive systemic anaphylaxis in vivo. This effect of PLA2G3 seems to be cell-intrinsic and related, at least in part, to the ability of PLA2G3 to promote normal maturation of mast cell granules (e.g., PLA2G3-deficient mast cells have substantially reduced amounts of histamine and granulestored proteases) and in part to its ability to enhance levels of surface FceRI. These data convincingly identify an important role for mast cell-derived PLA2G3 in mast cell maturation and function, but do not rule out potential contributions of PLA2G3 derived from other cell types. Indeed, the authors showed that Pla2g3 is also expressed in bone marrowderived mouse basophils, but they did not comment on possible production of PLA2G3 by other hematopoietic cells, such as neutrophils and eosinophils. In this regard, the decreased cutaneous anaphylaxis observed in Pla2g3-deficient mice actively sensitized with ovalbumin and alum might also be related to PLA2G3 deficiency in basophils or neutrophils, since the dependency of this model on mast cells alone was not directly tested.

The authors also used a mast cell-fibroblast co-culture system to provide an additional line of evidence that PLA2G3 is important for normal mast cell maturation. By analyzing

different transgenic mouse models targeting components of lipid pathways with potential effects on mast cell maturation or function (e.g., via actions of eicosanoid mediators)<sup>12</sup>, Taketomi et al. investigated the hypothesis that the observed effects of PLA2G3 on mast cells are associated with the role of PLA2G3 in lipid metabolism. Like Pla2g3<sup>-/-</sup> mice, Ptgdr<sup>-/-</sup> mice, which are systemically deficient in DP-1 (prostaglandin D receptor-1, which is expressed in several different cell types), or *Ptgds*<sup>-/-</sup> mice, deficient in L-PGDS, an enzyme involved in PGD<sub>2</sub> synthesis that is expressed by fibroblasts, developed abnormal mast cell phenotypes and attenuated passive cutaneous anaphylaxis. Upon co-culture with wild type fibroblasts, mast cells derived from Ptgdr-/- mice exhibited markedly reduced enhancement of expression of histidine decarboxylase (HDC), an enzyme required for mast cell histamine synthesis and for normal formation of cytoplasmic granules. Furthermore, wild type mast cells co-cultured with L-PGDS-deficient fibroblasts also exhibited impaired granule formation and decreased expression of HDC, implying that maturational effects of fibroblast L-PGDS require mast cell expression of DP-1. Finally, the authors provided evidence that this fibroblast-associated, lipid-based mast cell maturation pathway also exists in humans. Specifically, the robust HDC expression observed in human lung mast cells after co-culture with lung fibroblasts was significantly decreased by neutralization of PLA2G3, L-PGDS or DP-1. These novel findings, based on an impressive amount of work, support a model in which mast cell-secreted PLA2G3 (Fig. 1, step 7) induces the expression of fibroblast-derived PGD<sub>2</sub> synthase (L-PGDS) (Fig. 1, step 8), leading to increased local production of PGD<sub>2</sub> which in turn promotes mast cell maturation via DP-1 receptors (Fig. 1, step 9).

A notable conclusion of this study is that PLA2G3 not only can activate mast cells (as has been shown previously for other mammalian  ${\rm sPLA_{2}s^{7,8}}$ ) but can also contribute to mast cell maturation in the tissues. In this case, the molecule of interest was shown first to be a mast cell activator and then a contributor to mast cell maturation. By contrast, SCF was originally described as a critical mast cell survival and maturation factor, but subsequent studies showed that SCF also can activate mast cells directly and can enhance IgE- and antigendependent mast cell activation<sup>1,3</sup>. It is tempting to speculate that such a dual role in enhancing mast cell maturation, as well as in certain circumstances directly inducing and/or enhancing mast cell secretory function, might emerge as a feature shared by many mast cell "maturation factors".

An obvious goal for future studies is to understand in detail the mechanisms leading to the enhanced production of fibroblast L-PGDS upon PLA2G3 release by mast cells, and subsequently to local PGD<sub>2</sub> generation contributing to mast cell maturation. While one can speculate that the enzymatic activity of PLA2G3 plays an important role in this paracrine interaction pathway, an additional mechanism might involve the direct interaction of PLA2G3's unique N- or C-terminal domains with molecules expressed by fibroblasts or other structural cells<sup>5</sup>. It also will be interesting to determine whether other mast cell-secreted factors can importantly contribute to this process (Fig. 1, **step 7**), and to assess in detail how features of this axis are influenced by SCF, which can augment the IgE-dependent generation of PGD<sub>2</sub> by mouse mast cells at least in part by up-regulating the mast cell expression of the three enzymes in the pathway which generates PGD<sub>2</sub> from membrane phospholipids: cPLA<sub>2</sub>, prostaglandin H synthase, and hematopoietic PGDS<sup>12</sup>.

The work of Taketomi *et al.* thus makes important contributions to our understanding of the potential roles of secreted phospholipases and lipid mediators in paracrine and autocrine mechanisms contributing to the regulation of mast cell development and function. Their fascinating observations also suggest that additional findings of interest remain to be uncovered by extending such investigations to other types of hematopoietic cells.

## References

 Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets. Immunity. 2012; 37:25–33. [PubMed: 22840841]

- Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012; 18:693–704. [PubMed: 22561833]
- 3. Galli SJ, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005; 23:749–786. [PubMed: 15771585]
- 4. Taketomi Y, et al. Mast cell maturation is driven via a novel group III phospholipase  $A_2$ -prostaglandin  $D_2$ -DP1 receptor paracrine axis. Nat Imm. 2013
- Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A<sub>2</sub> enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011; 111:6130–6185. [PubMed: 21910409]
- 6. Murakami M, Lambeau G. Emerging roles of secreted phospholipase  $A_2$  enzymes: an update. Biochimie. 2013; 95:43–50. [PubMed: 23022039]
- Varsani M, Pearce FL. Role of phospholipase A<sub>2</sub> in mast cell activation. Inflamm Res. 1997; 46 (Suppl 1):S9–10. [PubMed: 9098740]
- 8. Murakami M, Hara N, Kudo I, Inoue K. Triggering of degranulation in mast cells by exogenous type II phospholipase A<sub>2</sub>. J Immunol. 1993; 151:5675–5684. [PubMed: 8228255]
- 9. Murakami M, Kudo I, Suwa Y, Inoue K. Release of 14-kDa group-II phospholipase A<sub>2</sub> from activated mast cells and its possible involvement in the regulation of the degranulation process. Eur J Biochem. 1992; 209:257–265. [PubMed: 1382985]
- 10. Pungercar J, Krizaj I. Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A<sub>2</sub>. Toxicon. 2007; 50:871–892. [PubMed: 17905401]
- 11. Valentin E, Ghomashchi F, Gelb MH, Lazdunski M, Lambeau G. Novel human secreted phospholipase A<sub>2</sub> with homology to the group III bee venom enzyme. J Biol Chem. 2000; 275:7492–7496. [PubMed: 10713052]
- 12. Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev. 2007; 217:168–185. [PubMed: 17498059]




Figure 1. Endogenous PLA2G3 can promote mast cell maturation and induce and enhance mast cell activation

Exogenous phospholipase A<sub>2</sub> (PLA<sub>2</sub>) contained in venoms of different species (1), and mammalian sPLA<sub>2</sub>s (secreted by various cell types) (2), can induce mast cell degranulation and mediator release. Mammalian sPLA<sub>2</sub>s are also involved in many other biological processes, including defense against bacteria and viruses (3). Taketomi et al. show that PLA2G3 (which can be produced by mast cells) can induce mast cell degranulation directly (4) and also can enhance antigen- and IgE-dependent mast cell degranulation (not shown). These findings suggest the following model of how PLA2G3 can promote mast cell maturation in peripheral tissues. Stem cell factor (SCF) produced by fibroblasts binds to and induces dimerization of its receptor c-Kit on mast cells (5). c-Kit signaling enhances mast cell survival and promotes mast cell maturation and, under certain circumstances, also can induce mast cells to secrete PLA2G3 (6). Mast cell-secreted PLA2G3, in the presence of an additional, presumably mast cell-derived, factor(s) yet to be identified, interacts with fibroblasts, in a way that remains to be determined (7), and increases expression of the prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) synthesizing enzyme L-PGDS (8). Fibroblast L-PGDS supplies a local pool of PGD<sub>2</sub>, which, by binding to DP1 expressed by mast cells, locally contributes to terminal mast cell maturation (9), inducing increasing the mast cell's content of cytoplasmic granule-associated mediators, e.g., histamine and proteases, and also increasing surface levels of FceRI (not shown). Such "maturation effects" prime tissue mast cells to respond more strongly to stimulation with IgE and specific antigen and thus contribute to the intensity of IgE-dependent biological responses (not shown).